Meta-Analysis of Cutaneous Adverse Reactions Induced by Dabrafenib Combined with Trametinib in the Treatment of Melanoma

Abstract

Abstract:

〔Abstract〕 Objective： To systematically evaluate the incidence of cutaneous adverse reactions induced by dabrafenib combined with trametinib in the treatment of melanoma. Methods： PubMed， EMbase， Cochrane Library， Web of Science， CNKI， VIP， Wanfang and China Biomedical Literature Database were searched by computer， and relevant published studies at home and abroad were collected. The retrieval period was from the establishment of the database to December 2020. Stata 15.1 software was used to calculate the incidence of cutaneous adverse reactions. RevMan 5.3 software was used to assess the relative risk（RR） for all grades of cutaneous adverse reactions. Results： A total of 10 studies involving 2 623 patients were included. The incidence of cutaneous adverse reactions of all grades in the treatment of melanoma with dabrafenib combined with trametinib were as follows：exanthem 22%［95%CI（0.19， 0.26）］， pruritus 10%［95%CI（0.08， 0.11）］， hyperkeratosis 7%［95%CI（0.04， 0.10）］， alopecia 5%［95%CI（0.04， 0.07）］， cutaneous papilloma 1%［95%CI（0.01， 0.03）］， acneiform dermatitis 10%［95%CI（0.06， 0.14）］， cutaneous squamous cell carcinoma 2%［95%CI（0.00， 0.04）］， dry skin 10% ［95%CI （0.08， 0.12）］ and erythema 11%［95%CI（0.09， 0.13）］. Compared with BRAF inhibitor alone， dabrafenib combined with trametinib reduced the incidence of pruritus， hyperkeratosis， alopecia， cutaneous papilloma， and cutaneous squamous cell carcinoma（P<0.05）. Conclusion： Exanthem is a common cutaneous adverse reaction in patients with melanoma treated with darafenib combined with trametinib. Compared with BRAF inhibitor alone， the combination drug significantly reduced the occurrence of cutaneous adverse reactions.

Key words:

"> ">〔Key words">〕 melanoma">； dabrafenib">； trametinib">； cutaneous adverse reactions">； Meta-analysis

CLC Number:

Wang Ruihang, Liu Xiaobo, Liao Ｓi, Hua Peng.

Meta-Analysis of Cutaneous Adverse Reactions Induced by Dabrafenib Combined with Trametinib in the Treatment of Melanoma [J]. Journal of Dali University, 2022, 7(4): 12-20.

References

〔1〕 DIRK S， ALEXANDER C J V A， CAROLA B， et al. Melanoma〔J〕.Lancet，2018，392（10151）：971-984.

〔2〕 Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma〔J〕.Cell，2015，161（7）：1681-1696.

〔3〕 LONG G V， STROYAKOVSKIY D， GOGAS H， et al. Dabrafenib and Trametinib versus Dabrafenib and Placebo for Val600 BRAF-Mutant Melanoma： A Multicentre， Doubleblind， Phase 3 Randomised Controlled Trial〔J〕.Lancet，2015，386（9992）：444-451.

〔4〕 ROBERT C， KARASZEWSKA B， SCHACHTER J， et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib〔J〕.N Engl J Med，2015，372（1）：30-39.

〔5〕 LONG G V， HAUSCHILD A， SANTINAMI M， et al. Adjuvant Dabrafenib plus Trametinib in Stage Ⅲ BRAF-Mutated Melanoma〔J〕.N Engl J Med，2017，377（19）：1813-1823.

〔6〕 ALGAZI A P， OTHUS M， DAUD A I， et al. Continuous versus Intermittent BRAF and MEK Inhibition in Patients with BRAF-Mutated Melanoma： A Randomized Phase 2 Trial〔J〕.Nat Med，2020，26（10）：1564-1568.

〔7〕 FLAHERTY K T， INFANTE J R， DAUD A， et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations〔J〕.N Engl J Med，2012，367（18）：1694-1703.

〔8〕 ASCIERTO P A， FERRUCCI P F， FISHER R， et al. Dabrafenib， Trametinib and Pembrolizumab or Placebo in BRAF-Mutant Melanoma〔J〕.Nat Med，2019，25（6）：941-946.

〔9〕 LARKIN J， ASCIERTO P A， DRNO B， et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melano-ma〔J〕.N Engl J Med，2014，371（20）：1867-1876.

〔10〕 DUMMER R， ASCIERTO P A， GOGAS H J， et al. Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma （COLUMBUS）： A Multicentre， Open-Label， Randomised Phase 3 Trial〔J〕.Lancet Oncol，2018，19（5）：603-615.

〔11〕 KANDOLF S L， PERIS K， HAUSCHILD A， et al. More than 5 000 Patients with Metastatic Melanoma in Europe per Year Do Not Have Access to Recommended First-Line Innovative Treatments〔J〕.Eur J Cancer，2017，75：313-322.

〔12〕 JADAD A R， MOORE R A， CARROLL D， et al. Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary？〔J〕. Control Clin Trials，1996，17（1）：1-12.

〔13〕 STANG A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses〔J〕.Eur J Epidemiol，2010，25（9）：603-605.

〔14〕 SCHREUER M， JANSEN Y， PLANKEN S， et al. Combination of Dabrafenib plus Trametinib for BRAF and MEK Inhibitor Pretreated Patients with Advanced BRAFV600-Mutant Melanoma： An Open-Label， Single Arm， Dual-Centre， Phase 2 Clinical Trial〔J〕.Lancet Oncol，2017，18（4）：464-472.

〔15〕 DAVIES M A， SAIAG P， ROBERT C， et al. Dabrafenib plus Trametinib in Patients with BRAFV600-Mutant Melanoma Brain Metastases （COMBI-MB）： A Multicentre， Multicohort， Open-Label， Phase 2 Trial〔J〕.Lancet Oncol，2017，18（7）：863-873.

〔16〕 JOHNSON D B， FLAHERTY K T， WEBER J S， et al. Combined BRAF （Dabrafenib） and MEK Inhibition （Trame-tinib） in Patients with BRAFV600-Mutant Melanoma Experiencing Progression with Single-agent BRAF Inhi-bitor〔J〕.J Clin Oncol，2014，32（33）：3697-3704.

〔17〕 SI L， ZHANG X S， SHIN S J， et al. Open-Label， Phase Ⅱa Study of Dabrafenib plus Trametinib in East Asian Patients with Advanced BRAF V600-Mutant Cutaneous Melanoma〔J〕.Eur J Cancer，2020，135：31-38.

〔18〕 SINHA R， LARKIN J， GORE M， et al. Cutaneous Toxicities Associated with Vemurafenib Therapy in 107 Patients with BRAF V600E Mutation-Positive Metastatic Melanoma， Including Recognition and Management of Rare Presentations〔J〕.Br J Dermatol，2015，173（4）：1024-1031.

〔19〕 PENG C， JIE X L. The Incidence and Risk of Cutaneous Toxicities Associated with Dabrafenib in Melanoma Patients： A Systematic Review and Meta-Analysis〔J〕.Euro J Hosp Pharm，2020，28（4）：182-189.

〔20〕 BOADA A， CARRERA C， SEGURA S， et al. Cutaneous Toxicities of New Treatments for Melanoma〔J〕.Clin Transl Oncol，2018，20（11）：1373-1384.

〔21〕 GNANENDRAN S S， TURNER L M， MILLER J A，et al. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors〔J〕.Curr Treat Options Oncol，2020，21（4）：29.

〔22〕 ZIMMER L， LIVINGSTONE E， HILLEN U， et al. Panniculitis with Arthralgia in Patients with Melanoma Treated with Selective BRAF Inhibitors and Its Manage-ment〔J〕.Arch Dermatol，2012，148（3）：357-361.

〔23〕 MCLELLAN B， KERR H. Cutaneous Toxicities of the Multikinase Inhibitors Sorafenib and Sunitinib〔J〕.Derma-tol Ther，2011，24（4）：396-400.

〔24〕 SACHSE M M， WAGNER G. Clearance of BRAF Inhibitor-Associated Keratoacanthomas by Systemic Retinoids〔J〕.Br J Dermatol，2014，170（2）：475-477.

〔25〕 WU J H， COHEN D N， RADY P L， et al. BRAF Inhibitor-Associated Cutaneous Squamous Cell Carci-noma： New Mechanistic Insight， Emerging Evidence for Viral Involvement and Perspectives on Clinical Manage-ment〔J〕.Br J Dermatol，2017，177（4）：914-923.

〔26〕 BELOW J， HOMEY B， GERBER P A. Kutane Nebenwir-

kungen Zielgerichteter Onkologischer Arzneimittel〔J〕.Hautarzt，2017，68（1）：12-18.

〔27〕 FAJE A T， LAWRENCE D， FLAHERTY K， et al. High-Dose Glucocorticoids for the Treatment of Ipilimu-mab-Induced Hypophysitis Is Associated with Reduced Survival in Patients with Melanoma〔J〕.Cancer，2018，124（18）：3706-3714.

[1]	Ou Ling, Li Cailin, Li Yinrui, Zhou Jie, Shan Wanxin, Wu Dingyu, Peng Fang. In vitro Study on the Periplaneta americana Polypepticde PAE2 Reversing Multi-Drug Resistance of BEL-7402/5-FU Based on AMPK-Regulated Autophagy [J]. Journal of Dali University, 2022, 7(4): 1-7.
[2]	Qing Chen, Chen Jinghu, Li Bolong, Liu Heng, Zhang Chenggui. Comparative Analysis of Liposoluble Constituents in the Larvae and Adults of Black Soldier Fly by GC-MS [J]. Journal of Dali University, 2022, 7(4): 8-11.
[3]	Hong Wenjuan, Zou Jiulin, Yu Zhuorui, Cheng Jiamao, He Minhua. Effects of SGLT2i on Bone Metabolism in Nephrotic Syndrome Model Rats [J]. Journal of Dali University, 2022, 7(4): 21-25.
[4]	Li Bin, Li Sufen, Yang Na, Xiong Wei. Expression and Significance of THBS2 Gene mRNA in Human Malignant Pleural Mesothelioma Based on Tumor Databases [J]. Journal of Dali University, 2022, 7(4): 26-33.
[5]	Duan Yi, Ni Changwen, Wang Minhua, Sun Sujiao, Huang Ling. Effects of the 7-Hydroxyisoflavone in the Proliferative Activity of HaCaT Cells and UVB-induced Photodamage [J]. Journal of Dali University, 2022, 7(4): 34-39.
[6]	Huang Zhong, Jia Ruipeng, Liu Yiheng, Zhang Chao, Liu Ke. Analysis of Risk Factors for Bone Cement Leakage during Percutaneous Kyphoplasty [J]. Journal of Dali University, 2022, 7(4): 40-43.
[7]	Luo Xinlei, Zhao Hui, Bai Tao, Xu Song, Zhang Xiongwen, Na Qiang. Analysis of Influencing Factors of New Fractures after Osteoporotic Vertebral Compression Fracture Surgery [J]. Journal of Dali University, 2022, 7(4): 44-46.
[8]	Xu Sanxiong, Zhang Jiyuan, Ma Xueying, Wei Guosong, Li Lin. Comparison of Curative Effects of MIS-TLIF and PLIF in the Treatment of Single-Segment Lumbar Degenerative Diseases [J]. Journal of Dali University, 2022, 7(4): 47-51.
[9]	Liu Siyuan, Rao Tao, Zhao Heng, Dou Jichen, Zhou Yi, Liu Qinghua, Cun Ｘinhua, . Clinical Evaluation of Oblique Lateral Interbody Fusion in the Treatment of Elderly Patients with Lumbar Tuberculosis [J]. Journal of Dali University, 2022, 7(4): 52-56.
[10]	Hu Jianhua, Hu Qi, Gao Guoxi, Lian Xingye, Yang Zhao, Zhang Chao. Analysis of the Treatment of Early Incision Deep Infection after Posterior Lumbar Internal Fixation and Fusion [J]. Journal of Dali University, 2022, 7(4): 57-59.
[11]	Gao Guoxi, Lian Xingye, Liu Weibing, Zhang Jun, Hu Jianhua, Lei Yunkun, Yang Zhao, Zhang Chao. Analysis of Clinical Treatment of Lumbar Brucellosis [J]. Journal of Dali University, 2022, 7(4): 60-62.
[12]	Peng Yunchuan, Luo Ting, Qi Lin, Ma Hongbing. Clinical Application of Improved Preoperative Preparation Method for DAA Total Hip Arthroplasty [J]. Journal of Dali University, 2022, 7(4): 63-65.
[13]	Wang Hongping, Yang Xiaoqin, Tao Qifeng, Wang Mingyou, Lan Yuping. Observation on the Short-Term Effect of Enhanced Recovery after Surgery Concept Combined with Artificial Femoral Head Replacement in the Treatment of Elderly Intertrochanteric Fractures [J]. Journal of Dali University, 2022, 7(4): 66-70.
[14]	Song Xunzhou, Wang Hongping, Lan Yuping. Application of Enhanced Recovery after Surgery Concept in Perioperative Period of Total Knee Arthroplasty [J]. Journal of Dali University, 2022, 7(4): 71-74.
[15]	Feng Yipeng, Dou Can, Wang Xiaoping, Chen Hongyun, Li Jiangyan. Analysis on the Quality of Life and Influencing Factors among Some Primary School Teachers in a Certain Area of Dali Bai Autonomous Prefecture [J]. Journal of Dali University, 2022, 7(4): 75-80.